Download PDF
CC BY-NC-ND 4.0 · World J Nucl Med 2022; 21(04): 329-333
DOI: 10.1055/s-0042-1750395
Case Report

Atypical Presentation of Marginal Zone Lymphoma as Isolated Diffuse Bone Marrow Involvement: Utility of F-18 FDG PET/CT in Diagnosis and Response Assessment

Dinesh Kumar Gauthaman
1   Department of Nuclear Medicine & Molecular Imaging, Amrita Institute of Medical Sciences, Kochi, Kerala, India
,
Padma Subramanyam
1   Department of Nuclear Medicine & Molecular Imaging, Amrita Institute of Medical Sciences, Kochi, Kerala, India
,
Shanmuga Sundaram Palaniswamy
1   Department of Nuclear Medicine & Molecular Imaging, Amrita Institute of Medical Sciences, Kochi, Kerala, India
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Non-Hodgkin's lymphoma (NHL) with secondary bone marrow involvement is relatively common. However, isolated involvement of bone marrow in marginal zone type of NHL is atypical and rare. Here, we describe a patient of atypical marginal zone lymphoma with isolated bone marrow involvement who presented with weight loss and bicytopenia, where F-18 FDG PET/CT (fluorine-18-labeled fluorodeoxyglucose positron emission tomography with computed tomography) imaging played a pivotal role in establishing the diagnosis when conventional imaging modalities were unremarkable. The patient was successfully treated with systemic chemotherapy (rituximab, cyclophosphamide, prednisolone) and achieved complete remission, as demonstrated by a follow-up F-18 FDG PET/CT scan.

Keywords

marginal zone lymphoma - F-18 FDG PET/CT - isolated bone marrow involvement - atypical presentation - case report


Publication History

Article published online:
05 September 2022

© 2022. World Association of Radiopharmaceutical and Molecular Therapy (WARMTH). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Boveri E, Arcaini L, Merli M. et al. Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients. Ann Oncol 2009; 20 (01) 129-136
    CrossrefPubMedGoogle Scholar
  • 2 Cheson BD, Fisher RI, Barrington SF. et al; Alliance, Australasian Leukaemia and Lymphoma Group,, Eastern Cooperative Oncology Group,, European Mantle Cell Lymphoma Consortium,, Italian Lymphoma Foundation,, European Organisation for Research, Treatment of Cancer/Dutch Hemato-Oncology Group,, Grupo Español de Médula Ósea,, German High-Grade Lymphoma Study Group,, German Hodgkin's Study Group,, Japanese Lymphorra Study Group,, Lymphoma Study Association, NCIC Clinical Trials Group,, Nordic Lymphoma Study Group,, Southwest Oncology Group,, United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32 (27) 3059-3068
    CrossrefPubMedGoogle Scholar
  • 3 Albano D, Bertoli M, Ferro P. et al. 18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience. Eur J Nucl Med Mol Imaging 2017; 44 (04) 589-597
    CrossrefPubMedGoogle Scholar
  • 4 Albano D, Giubbini R, Bertagna F. 18F-FDG PET/CT in splenic marginal zone lymphoma. Abdom Radiol (NY) 2018; 43 (10) 2721-2727
    CrossrefPubMedGoogle Scholar
  • 5 Vaxman I, Bernstine H, Kleinstern G. et al. FDG PET/CT as a diagnostic and prognostic tool for the evaluation of marginal zone lymphoma. Hematol Oncol 2019; 37 (02) 168-175
    CrossrefPubMedGoogle Scholar
  • 6 Carrillo-Cruz E, Marín-Oyaga VA, de la Cruz Vicente F. et al. Role of 18F-FDG-PET/CT in the management of marginal zone B cell lymphoma. Hematol Oncol 2015; 33 (04) 151-158 Erratum in: Hematol Oncol. 2016;34(2):117
    CrossrefPubMedGoogle Scholar
  • 7 Treglia G, Zucca E, Sadeghi R, Cavalli F, Giovanella L, Ceriani L. Detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta-analysis. Hematol Oncol 2015; 33 (03) 113-124
    CrossrefPubMedGoogle Scholar
  • 8 Zucca E, Arcaini L, Buske C. et al; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31 (01) 17-29
    CrossrefPubMedGoogle Scholar
  • 9 Barrington SF, Mikhaeel NG, Kostakoglu L. et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014; 32 (27) 3048-3058 Erratum in: J Clin Oncol. 2016;34(21):2562
    CrossrefPubMedGoogle Scholar
  • 10 Elamir Y, Elazab M, Owis A, Elsayad HF. PET/CT and bone marrow biopsy (BMB) in evaluating bone marrow in lymphoma. Egypt J Radiol Nucl Med 2020; 51: 201
    CrossrefGoogle Scholar